Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Brief Summary: This phase III trial studies olaparib or cediranib maleate and olaparib to see how well they work compared with standard platinum-based chemotherapy in treating patients with platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer that has come back. Olaparib and cediranib maleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Cediranib maleate may stop the growth of ovarian, fallopian tube, or primary peritoneal cancer by blocking the growth of new blood vessels necessary for tumor growth. Drugs used in chemotherapy, such as carboplatin, paclitaxel, gemcitabine hydrochloride, and pegylated liposomal doxorubicin hydrochloride work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether olaparib or cediranib maleate and olaparib is more effective than standard platinum-based chemotherapy in treating patients with platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer.


Options:
A: Arm Label: Arm I (platinum-based chemotherapy); Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Procedure: Computed Tomography, Procedure: Echocardiography Test, Drug: Gemcitabine, Drug: Gemcitabine Hydrochloride, Other: Laboratory Biomarker Analysis, Procedure: Magnetic Resonance Imaging, Procedure: Multigated Acquisition Scan, Drug: Paclitaxel, Drug: Pegylated Liposomal Doxorubicin Hydrochloride, Other: Quality-of-Life Assessment | Arm Label: Arm II (olaparib); Type: EXPERIMENTAL; Interventions: Procedure: Biospecimen Collection, Procedure: Computed Tomography, Procedure: Echocardiography Test, Other: Laboratory Biomarker Analysis, Procedure: Magnetic Resonance Imaging, Procedure: Multigated Acquisition Scan, Drug: Olaparib, Other: Pharmacological Study, Other: Quality-of-Life Assessment | Arm Label: Arm III (olaparib, cediranib maleate); Type: EXPERIMENTAL; Interventions: Procedure: Biospecimen Collection, Drug: Cediranib Maleate, Procedure: Computed Tomography, Procedure: Echocardiography Test, Other: Laboratory Biomarker Analysis, Procedure: Magnetic Resonance Imaging, Procedure: Multigated Acquisition Scan, Drug: Olaparib, Other: Pharmacological Study, Other: Quality-of-Life Assessment | Intervention Type: PROCEDURE; Name: Biospecimen Collection; Assigned to Arm(s): Arm II (olaparib), Arm III (olaparib, cediranib maleate) | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Arm I (platinum-based chemotherapy) | Intervention Type: DRUG; Name: Cediranib Maleate; Assigned to Arm(s): Arm III (olaparib, cediranib maleate) | Intervention Type: PROCEDURE; Name: Computed Tomography; Assigned to Arm(s): Arm I (platinum-based chemotherapy), Arm II (olaparib), Arm III (olaparib, cediranib maleate) | Intervention Type: PROCEDURE; Name: Echocardiography Test; Assigned to Arm(s): Arm I (platinum-based chemotherapy), Arm II (olaparib), Arm III (olaparib, cediranib maleate) | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): Arm I (platinum-based chemotherapy) | Intervention Type: DRUG; Name: Gemcitabine Hydrochloride; Assigned to Arm(s): Arm I (platinum-based chemotherapy) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm I (platinum-based chemotherapy), Arm II (olaparib), Arm III (olaparib, cediranib maleate) | Intervention Type: PROCEDURE; Name: Magnetic Resonance Imaging; Assigned to Arm(s): Arm I (platinum-based chemotherapy), Arm II (olaparib), Arm III (olaparib, cediranib maleate) | Intervention Type: PROCEDURE; Name: Multigated Acquisition Scan; Assigned to Arm(s): Arm I (platinum-based chemotherapy), Arm II (olaparib), Arm III (olaparib, cediranib maleate) | Intervention Type: DRUG; Name: Olaparib; Assigned to Arm(s): Arm II (olaparib), Arm III (olaparib, cediranib maleate) | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm I (platinum-based chemotherapy) | Intervention Type: DRUG; Name: Pegylated Liposomal Doxorubicin Hydrochloride; Assigned to Arm(s): Arm I (platinum-based chemotherapy) | Intervention Type: OTHER; Name: Pharmacological Study; Assigned to Arm(s): Arm II (olaparib), Arm III (olaparib, cediranib maleate) | Intervention Type: OTHER; Name: Quality-of-Life Assessment; Assigned to Arm(s): Arm I (platinum-based chemotherapy), Arm II (olaparib), Arm III (olaparib, cediranib maleate)
B: Arm Label: Patupilone; Type: EXPERIMENTAL; Interventions: Drug: EPO906 (Patupilone) | Arm Label: doxorubicin; Type: ACTIVE_COMPARATOR; Interventions: Drug: doxorubicin | Intervention Type: DRUG; Name: EPO906 (Patupilone); Assigned to Arm(s): Patupilone | Intervention Type: DRUG; Name: doxorubicin; Assigned to Arm(s): doxorubicin
C: Arm Label: pazopanib; Type: EXPERIMENTAL; Interventions: Drug: Pazopanib | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo comparator | Intervention Type: DRUG; Name: Pazopanib; Assigned to Arm(s): pazopanib | Intervention Type: DRUG; Name: Placebo comparator; Assigned to Arm(s): placebo
D: Arm Label: A (reference); Type: PLACEBO_COMPARATOR; Interventions: N/A | Arm Label: B (concurrent cediranib); Type: ACTIVE_COMPARATOR; Interventions: Drug: cediranib | Arm Label: C (concurrent and maintenance cediranib); Type: ACTIVE_COMPARATOR; Interventions: Drug: cediranib | Intervention Type: DRUG; Name: cediranib; Assigned to Arm(s): B (concurrent cediranib), C (concurrent and maintenance cediranib)

Answer: A